Entering text into the input field will update the search result below

Genomic Health's (GHDX) CEO Kim Popovits on Q2 2018 Results - Earnings Call Transcript

Aug. 03, 2018 8:00 PM ETGenomic Health, Inc. (GHDX)
SA Transcripts profile picture
SA Transcripts

Genomic Health, Inc. (NASDAQ:GHDX) Q2 2018 Earnings Conference Call August 2, 2018 4:30 PM ET


Emily Faucette – Vice President of Corporate Communications and Investor Relations

Kim Popovits – Chairman of the Board, Chief Executive Officer and President

Brad Cole – Chief Financial Officer

Steve Shak – Chief Scientific Officer and Chief Medical Officer

Fred Pla – Chief Operating Officer


Mitch Petersen – Barclays

Tejas Savant – JPMorgan

Mark Massaro – Canaccord Genuity

Dan Leonard – Deutsche Bank


Good afternoon. My name is James, and I will be your conference operator today. At this time, I would like to welcome everyone to Genomic Health’s Second Quarter 2018 Financial Results Conference Call. Currently, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will be provided at that time. [Operator Instructions] As a reminder, this call is being recorded.

I would now like to turn the call over to Emily Faucette, Vice President of Corporate Communications and Investor Relations. You may begin your conference call.

Emily Faucette

Thank you. Good afternoon, everyone, and welcome to Genomic Health’s conference call to review our second quarter 2018 financial results. Please note, a copy of the prepared remarks we are about to make is available to download on the Investors section of our corporate website, genomichealth.com.

Before we begin, I’d like to remind you that various remarks that we make on this call are not historical, including those about our future financial and operating results; key drivers and expectations for revenue growth in 2018; demand for our tests and drivers of demand as well as correlations between test demand to present or future revenue; payer coverage, timing of revenues from payers and progress in reimbursement and patient access; clinical outcomes and the timing and impact of clinical studies and publications; our plans and

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.